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Objective: To examine the current medical management of arteriopathic patients attending a 
vascular surgical service at a university teaching hospital over a 6-month period. The   prescribing 
of antiplatelets, statins, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin   receptor 
blockers and beta-blockers was specifically examined. Vascular patients are often under the 
care of multiple specialties, and therefore the influence of different medical specialties on the 
patients’ medical management was also examined.
Design: Between January and June 2009, data were recorded on sequential patients with arterial 
disease attending the vascular surgical service. Patients’ demographics, type of arterial disease, 
medical consultations within the previous 12 months, and current medications were recorded.
Results: The study included 180 patients with a mean age of 69 years (39–88 years). All but 
4% were taking an antiplatelet or anticoagulant, predominantly aspirin. There were 86% taking 
a statin, 44% taking a beta-blocker, and 51% taking an ACE inhibitor. Suboptimal prescription 
of ACE inhibitors and beta-blockers was evident regardless of the type of medical consultations 
in the previous year. No specialty group differed significantly from vascular surgeons in their 
prescribing pattern.
Conclusions: While almost all arteriopaths receive some form of antiplatelet and statin in line 
with clinical evidence, ACE inhibitors and beta-blockers appear to be under-prescribed in this 
arteriopathic population. We conclude that opportunity exists for vascular surgeons to embrace 
recent guidelines and lead the way in both surgical and medical optimization of arteriopathic 
patients through improving links with primary care physicians or taking greater responsibility 
themselves for the medical as well as the surgical care of their arteriopathic patients.
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Introduction
Atherosclerosis is the leading cause of death in Western society. It is a systemic 
disease leading to arterial lesions which typically develop unnoticed. Peripheral arte-
rial disease (PAD) affects 12% of the population of the Western world.1 Intermittent 
  claudication is the most common symptom of mild to moderate PAD, occurring at 
an annual incidence of 2% in patients aged over 65 years.2 These patients are at 
  significantly higher risk of cardiovascular death compared to healthy controls of 
similar age.3
Vascular surgeons are uniquely placed to identify and initiate medical treatment 
in atherosclerotic patients, as well as to choose from the ever-expanding arsenal of 
endovascular and open procedures linked with advances in technology, techniques, 
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Two large multinational randomized controlled clinical 
trials (RCCTs) have shown that the use of angiotensin-
converting enzyme (ACE) inhibitors and statins in arterio-
pathic patients significantly improves both   morbidity and 
mortality (HOPE and Prospective Study of Pravastatin in 
the Elderly at Risk [PROSPER]).4,5 The benefits of ACE 
inhibitors appear to be independent of their antihypertensive 
effects. It is similarly proven that an antiplatelet medication 
independently reduces morbidity and overall mortality in 
arteriopathic patients.6 There is also strong evidence for 
beta-blockade of patients with a history of ischemic heart 
disease or an equivalent risk factor.
While smoking cessation and weight loss and exercise 
programs are commonly ‘prescribed’ interventions for arte-
riopaths, it is argued that all PAD patients (ankle–brachial 
index 0.9) should also be medically optimized with pre-
scription of all four drug subclasses mentioned above.7 In an 
observational study by Feringa et al,8 of 2420 consecutive 
patients (64 ± 11 years) with PAD, followed over a median 
of 8 years, of which 1067 patients (44%) died, after adjust-
ment for risk factors, statins (hazard ratio [HR] = 0.46), 
beta-blockers (HR = 0.68), aspirin (HR = 0.72), and ACE 
inhibitors (HR = 0.80) were all significantly associated with a 
reduced risk of long-term mortality. These HRs demonstrate 
a significant benefit for each of these four medications in a 
study population demographically very similar to our own 
study group.
We hypothesized that vascular patients presenting with 
arterial disease to a vascular surgical service are receiving 
suboptimal medical management relative to those with arte-
rial disease presenting to other specialties. The perceived 
enhanced influence by other medical specialties on this 
medical management was also examined.
Methods
Between January and June 2009, data were prospectively 
recorded on patients attending the vascular service at Cork 
University Hospital. Data were recorded by a member of the 
vascular surgical team on questionnaires completed at the 
time of inpatient admission or during an outpatient consulta-
tion. Inclusion criteria were patients with documented arterial 
disease or those with significant clinical symptoms being 
investigated for arterial disease. Patients’ demographics, 
location of arterial disease, prior medical consultations within 
the last 12 months, and current medications were recorded. A 
record of the patients’ prescribed medications was available 
at the time of consultation, and patient   compliance was con-
firmed. The patients were specifically asked if they had been 
seen by their general practitioner (GP), a   medical consultant, 
a cardiologist, or a member of the   vascular surgical team in 
the preceding 12 months.
Results
Data were collected on a total of 180 patients (143 males, 
37 females) with a mean age of 69 (39–88). Patients’ demo-
graphics, comorbidities, and medication use are presented 
in Table 1. The frequency of medication use is graphically 
represented in Figure 1.
Within the previous 12 months, 142/180 (79%) patients 
had seen a vascular surgeon (return patient), 142/180 (79%) 
had seen their GP, 62/180 (34%) a medical consultant, and 
33/180 (18%) a cardiologist (Figure 2). The majority (78%) 
of patients had seen more than one specialty in the previous 
12 months. Of note, 95/180 (53%) patients had seen only a GP, 
a vascular surgeon, or both in the previous 12 months. 
Only 40/180 (22%) had seen one specialty in the previous 
12 months (vascular 18/180, GP 14/180, medical 6/180, and 
cardiology 2/180). All 180 patients had been seen by at least 
one specialty in the previous 12 months. This is represented 
in a modified Venn diagram in Figure 3.
The study population was analyzed according to which 
of the four specialty groups had seen them in the previous 
12 months. It emerged that regardless of whether patients had 
Table 1 Patient details (n = 180)
Patient demographics
  Age (years, mean, range) 69 39–88
  sex (male:female) 143:37
Patient comorbidities number of patients %
  Claudication 111 61.7
  Coronary angio/stenting 11 6.1
  Peripheral angioplasty 17 9.4
  CABg 31 17.2
  Carotid disease 56 31.1
  Peripheral bypass 31 17.2
  AAA 23 12.7
  Mi/CVA 31 17.2
  Diabetes 38 21.1
Patient medication use
  Beta-blocker 79 43.8
  ACe inhibitor 79 43.8
  Angiotensin receptor blocker 13 7.2
  statin 155 86.1
  Aspirin 107 59.4
  Clopidogrel 12 6.7
  Aspirin and clopidogrel 36 20.0
  Warfarin 14 7.8
  Warfarin and aspirin 3 1.6
Abbreviations: AAA, abdominal aortic aneurysm; ACe, angiotensin-converting enzyme; 
CABg,  coronary  artery  bypass  graft;  CVA,  cardiovascular  accident;  Mi,  myocardial 
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seen a GP, vascular, medical, or cardiology doctor or any 
combination in the previous 12 months, prescribing patterns 
were similar. Suboptimal prescription of ACE inhibitors and 
beta-blockers was evident across all subgroups. The types 
of specialties seen in the previous 12 months did not appear 
to influence the prescribing patterns (with the exception of 
a minor increase in beta-blocker usage in those patients seen 
by a cardiologist). These results are charted in Figure 4.
Discussion
Almost all arteriopaths receive some form of antiplatelet 
and a statin in line with clinical evidence. However, ACE 
inhibitors and beta-blockers appear to be under-prescribed 
in this arteriopathic population despite significant evidence 
that they reduce morbidity and mortality in such patients. 
Several landmark randomized clinical control trials in recent 
years have identified clear guidelines for the best medical 
management of arteriopathic patients.
The use of antiplatelets in arteriopathic patients is 
well established. The benefits of antiplatelets are best 
described in a meta-analysis of 129 RCCTs published by the 
  Antiplatelet   Trialists’ Collaboration in the British Medical 
Journal in 1994.6 The meta-analysis included 100,000 
patients and demonstrated a 25% decrease in myocardial 
infarction (MI), stroke, and death in arteriopathic patients 
on low dose–  prolonged antiplatelet treatment. Since this 
publication, the prescription of antiplatelet therapy has 
increased significantly, as is clearly demonstrated in our 
study with 96% of patients on some form of antiplatelet 
or anticoagulant therapy. The use of the anticoagulant war-
farin in our study population was almost exclusively for 
risk reduction of embolic events secondary to the presence 
of atrial fibrillation and was not due to the presence of their 
arterial disease. However, the use of warfarin did deter the 
coprescribing of an antiplatelet due to the increased risk of 
bleeding complications, with only 3 of 17 patients on warfarin 
also receiving aspirin.
All arteriopathic patients should be prescribed HMG CoA 
reductase inhibitors (statins). Arteriopathic patients should 
be aggressively treated with a lipid-lowering therapy even 
if their baseline cholesterol levels are normal.9 Low-density 
lipoprotein (LDL) cholesterol should be the primary target of 
cholesterol-lowering therapy as a 1% reduction in LDL levels 
reduces the relative risk of a major cardiovascular event by 
1% over a 5-year period, independent of age, gender, and 
baseline levels.10 Statin therapy typically dropped LDL levels 
by 30%–40% in all of the treatment arms of the major clinical 
trials.5,9,11–13 The doses used are comparable to current clinical 
doses, representing a significant risk reduction benefit when 
used in arteripathic patients. PROSPER was a multicenter 
RCCT of pravastatin use in 5800 patients with vascular 
disease.5 Mortality from coronary artery disease fell by 24% 
in the pravastatin group. While the risk for stroke was unaf-
fected, the HR for transient ischemic attacks was 0.75 in the 
treatment group compared to placebo. As well as improving 
overall survival, statins improve symptoms of PAD through 
pleiotropic effects, thought to be mediated through a reduc-
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tion in endothelial dysfunction, plaque   stabilization, and 
anti-inflammatory effects.14,15 The Scandinavian Simvastatin 
Survival Study found a 38% decrease in ‘new or worsening 
claudication’ over a 5.4-year period in 4444 patients treated 
with simvastatin.13 This further supports the use of statins 
in vascular patients.
The use of beta-blockers is well established in cor-
onary artery disease. A meta-analysis of 82 RCCTs 
incorporating 54,000 patients demonstrated the effect of 
beta-blockade in long-term secondary prevention after MI 
with a proven reduction in mortality.16 Carotid artery disease, 
peripheral vascular disease, and abdominal aortic aneurysms 
are termed coronary risk equivalents as they represent a com-
parable increased risk of developing new coronary events 
equivalent to patients with established coronary artery disease 
(20% over 10 years). Patients with coronary risk equivalents 
should have the same target blood pressure as patients with 
coronary artery disease.17 The achievement of optimal blood 
pressure control appears more important than the antihyper-
tensive agent used in overall risk reduction in patients without 
established coronary artery disease. The prospective observa-
tional study by Feringa et al8 demonstrated a HR of 0.68 for 
patients with PAD receiving beta-blockers. In this study of 
2420 patients, beta-blockers were the second most beneficial 
drug after statins in reducing long-term mortality.
Unfounded fears have existed with regard to the use 
of beta-blockers in patients with intermittent claudication. 
A recent Cochrane review of six RCCTs of beta-blocker 
versus placebo in PAD showed no statistically significant 
worsening effect of beta-blockers on maximum walking 
distance, claudication distance, calf blood flow, or skin 
temperature.18 An earlier meta-analysis of 11 RCCTs again 
showed no evidence of adverse effects on walking capacity 
or symptoms of intermittent claudication in patients with 
mild to moderate PAD.19 Both of these publications support 
the use of beta-blockers in patients with coronary artery 
disease and PAD.
An observational study performed on 575 men and women, 
mean age 80 years, with symptomatic PAD and prior MI, 
demonstrated a 53% significant independent decrease in the 
incidence of new coronary events in this elderly population 
over a 32-month follow-up period when prescribed a beta-
blocker.20 This study recommended beta-blockers for these 
patients in the absence of contraindications to these drugs. 
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In the same study, 15% of patients were reported to have 
contraindications to beta-blockers, and of those patients that 
commenced beta-blockade, 12% discontinued treatment due 
to adverse effects. Although this elderly cohort of patients 
is likely to have more contraindications and adverse side 
effects to beta-blockers than our younger study population, 
73% of its patients were eligible for long-term beta-blockade. 
This compares to only 44% of our patient group on long-
term beta-blockade. Consequentially, contraindications and 
adverse effects to beta-blockers are unlikely to explain this 
low prescribing rate in our own study population.
The increased use of beta-blockers in patients in the 
  cardiology group of our study relative to the other groups can 
be explained by the increased recognition of   established coro-
nary artery disease within this group. An under-  recognition 
of ‘coronary risk equivalents’ in the other groups may be 
leading to the under-prescription of beta-blockers in all 
of these high-risk patients. The cardioprotective effects of 
beta-blockers make them an important treatment option 
for risk reduction in vascular patients without specific 
  contraindications to beta-blockade.
ACE inhibitors act on the renin–angiotensin–aldosterone 
system by inhibiting the ACE-mediated conversion of 
angiotensin I to angiotensin II. Angiotensin II is a potent 
vasoconstrictor. Within the kidneys, angiotensin II prefer-
entially constricts the efferent arterioles leading to increased 
perfusion pressure in the glomeruli. It is a drop in this 
glomerular filtration pressure that initially stimulates renin 
release. Angiotensin II also stimulates the adrenal cortex 
to release aldosterone, which causes retention of sodium 
and excretion of potassium in the kidneys which leads to 
increased water retention, blood volume, and consequentially 
blood pressure. It also stimulates the release of antidiuretic 
hormone from the posterior pituitary which again increases 
water retention and increases blood pressure. By blocking 
the conversion of angiotensin I to angiotensin II with ACE 
inhibitors,   antihypertensive effects are achieved.
However, ACE inhibitors have been shown to reduce 
the cardiovascular morbidity and mortality rates in patients 
with peripheral vascular disease by 25% regardless of the 
presence or absence of hypertension. This was demonstrated 
eloquently in the HOPE trial, a multicenter international 
RCCT with 9000 high-risk vascular patients assigned to 
either a placebo group or a ramipril (10 mg) group.4 In fact, 
the beneficial effects of ramipril were so evident that the 
trial was concluded after only 2 years instead of the initially 
planned 4.5 years. The 2006 AHA/ACC guidelines state 
that it is reasonable to treat patients with peripheral vascular 
disease with ACE inhibitors to reduce the risk of adverse 
cardiovascular events. As well as reducing mortality, a small 
double-blind placebo-controlled trial published by   Ahimastos 
in 2006 demonstrated that ACE inhibitors improve the 
symptoms of peripheral vascular disease, increasing walking 
time by 200%, although the patient numbers were small 
and patients with hypertension and diabetes were   excluded.21 
Data from the same cohort of patients suggested that this 
improvement was due to reduced arterial wall stiffness 
caused by ACE inhibitors in the treatment group.22 Like 
statins, ACE inhibitors have pleiotropic vascular protective 
effects including plaque stabilization, improved vasomotor 
dysfunction, and many biochemical mechanisms including 
inhibition of platelet adhesion and aggregation, inhibition of 
platelet-derived growth factor, endothelin, and stimulation 
of endothelial relaxation via stimulation of nitric oxide and 
prostacyclin.15
Despite the evidence for the use of ACE inhibitors being 
as compelling as those that support the use of antiplatelets 
and statins, there are significant differences in the prescribing 
rates seen in our study (51% vs 96%). Why do the major-
ity of vascular patients who should be treated with an ACE 
inhibitor remain untreated?
We feel that there is a perception among vascular sur-
geons that the prescription of aspirin and a statin is ‘safe,’ 
but that the prescription of ACE inhibitors and beta-blockers 
has traditionally been left as the responsibility of ‘medical’ 
doctors. This may be due to a lag time in embracing new 
guidelines or a fear of the contraindications and potential 
side effects of ACE inhibitors.
The contraindications to ACE inhibitors include bilateral 
renal artery stenosis (or unilateral with a solitary   functioning 
kidney) and angioedema associated with ACE inhibitor 
therapy in the past, both of which are rare. These contrain-
dications may be causing an overcautious reluctance among 
vascular surgeons to prescribe ACE inhibitors. In the HOPE 
trial, 0.5% of the ramipril group and 0.6% of the placebo 
group stopped treatment due to increase in serum creatinine.4 
This represents a very small incidence of renal impairment 
secondary to ACE inhibitors in a population that was at high 
risk for renal artery stenosis. It should be noted also that 
10 mg of ramipril was used in the HOPE trial, as opposed 
to 2.5 mg, which would be the current initial recommended 
starting dose.6
Side effects from ACE inhibitors are rare but include 
hypotension, renal impairment, angioedema, cough, and 
anaphylactoid reactions. In the ONTARGET trial, the largest 
clinical trial involving the use of ACE inhibitors, 1.7% of Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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8576 patients discontinued ramipril due to hypotension, 0.7% 
due to sufficient renal impairment, 3.3% due to hyperkalemia, 
0.3% due to angioedema, and 4.4% due to cough. A total of 
10.4% of patients discontinued treatment due to side effects 
from ramipril.23 The rare amount of contraindications and the 
side effect prevalence of 10.4% (as seen in the ONTARGET 
trial) can be dismissed as a possible explanation for the low 
prescribing level of ACE inhibitors within our study.
Some vascular patients may have preexisting renal impair-
ment especially with the high incidence of diabetes (21% in 
our study population), leading to diabetic nephropathy. ACE 
inhibitors have a proven renal protective effect in diabetic 
patients, independent of the antihypertensive effects.24,25 The 
same is true in nondiabetic patients. An RCCT of benazepril 
use in nondiabetic patients with advanced renal insufficiency 
found that the treatment group had a 43% reduction in the 
risk of doubling of serum creatinine, end stage renal disease, 
or death.26 ACE inhibition also reduced the rate of decline 
in renal function by 23%. Strong evidence exists proving 
the benefits of ACE inhibitors in vascular patients grossly 
outweigh the potential risks.
While we argue that the low prevalence of contrain-
dications and adverse side effects to ACE inhibitors and 
beta-blockers in previous studies make these an unlikely 
explanation for the low prescribing rate of these drugs in 
our own study, we accept that not specifically recording the 
contraindications and side effects from these drugs in our 
own study population is a weakness of our study. However, 
any medications that were temporarily stopped to facilitate 
an intravenous contrast study or another procedure at the 
time of data collection were regarded as being prescribed 
and taken.
The influence of gender on prescription was briefly 
  analyzed. There were four times as many men to women 
in the study population as would be typical of a vascular 
surgical service population. Prescription rates were similar, 
with 45% of men and 38% of women being prescribed 
beta-blockers. The same percentages were evident for ACE 
inhibitors, although the groups were made up of different 
individual patients.
Regarding the influence of the different medical specialties 
on prescribing rates, most patients attend   multiple specialties 
in parallel. Of note, in Ireland, all patients attending a specialty 
consultant must be initially referred by their family doctor 
(GP) or a consultant colleague and will not be seen directly 
without this referral. This partially explains the high rate of 
attendance to multiple specialties. This makes it difficult to 
attribute changes in prescribing patterns to the attendance of 
a patient to a specific specialty. As seen in Figure 2, a signifi-
cantly lower percentage of patients were seen by a cardiologist 
or a medical consultant. Although those patients who did see 
a cardiologist or medical   consultant appeared to have similar 
medication lists (Figure 4), the overall low percentage of 
patients reviewed by these   specialists may partially explain 
the under-prescription of ACE inhibitors and beta-blockers. 
The low prescribing rate of appropriate medications is more 
of a reflection of the entire health care system rather than 
that of the individual specialties. However, it emphasizes the 
importance of good quality communication among consul-
tants looking after patients with multiple comorbidites, and 
it particularly emphasizes the essential link required between 
hospital consultants and primary care physicians working in 
general practice. It is important to recognize that our study 
is a single-center study from   Ireland with a limited number 
of patients, and therefore, our findings may not be applicable 
to other health care systems and practices.
Conclusion
Vascular surgeons have unique access to arteriopathic 
patients. In our study population, 53% of patients had seen 
only a GP or a vascular surgeon in the preceding year. Of those 
patients who had seen only one doctor in the preceding year, 
the vascular surgeon had been the most commonly seen doc-
tor. These facts highlight the opportunity vascular surgeons 
must take in leading the medical optimization of arteriopathic 
patients. This is particularly the case in Ireland where the 
medical equivalent of the vascular surgeon, the ‘angiologist,’ 
does not exist, as seen in some European countries and North 
America. A comparison of the medical management of Irish 
and European arteriopathic patients may identify a need to 
develop this specialty role in countries where it is absent.
Overwhelming evidence exists in support of prescribing 
an antiplatelet agent, a statin, and an ACE inhibitor for all 
arteriopathic patients without specific contraindications. Beta-
blockers should also be used in patients with coronary artery 
disease or coronary risk equivalents. We have highlighted 
that while most vascular patients receive aspirin and a statin, 
approximately only half receive an ACE inhibitor or a beta-
blocker. This inconsistency in prescribing habits is evident 
across medical specialties. Vascular surgeons are uniquely 
placed to lead in the medical optimization of the arteriopathic 
patient population they serve through the increased use of ACE 
inhibitors as well as the continued use of antiplatelets and 
statins. Beta-blockers should remain the antihypertensive of 
choice in all patients with coronary artery disease or a coronary 
risk equivalent in the absence of contraindications.Vascular Health and Risk Management
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